Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ALKEM LABORATORIES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-23 |
TEVA PHARMA Dec-13 |
ALKEM LABORATORIES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,625 | 3,479 | - | |
Low | Rs | 2,835 | 3,022 | - | |
Sales per share (Unadj.) | Rs | 970.1 | 1,996.4 | - | |
Earnings per share (Unadj.) | Rs | 84.2 | 124.7 | - | |
Cash flow per share (Unadj.) | Rs | 110.2 | 286.1 | - | |
Dividends per share (Unadj.) | Rs | 50.00 | 109.18 | - | |
Avg Dividend yield | % | 1.5 | 3.4 | 46.1% | |
Book value per share (Unadj.) | Rs | 756.4 | 2,217.6 | - | |
Shares outstanding (eoy) | m | 119.57 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.3 | 1.6 | 204.5% | |
Avg P/E ratio | x | 38.4 | 26.1 | 147.2% | |
P/CF ratio (eoy) | x | 29.3 | 11.4 | 258.1% | |
Price / Book Value ratio | x | 4.3 | 1.5 | 291.3% | |
Dividend payout | % | 59.4 | 87.5 | 67.8% | |
Avg Mkt Cap | Rs m | 386,207 | 2,756,220 | 14.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 21,314 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,667.6 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,353.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 115,993 | 1,692,969 | 6.9% | |
Other income | Rs m | 2,161 | 0 | - | |
Total revenues | Rs m | 118,153 | 1,692,969 | 7.0% | |
Gross profit | Rs m | 15,065 | 463,620 | 3.2% | |
Depreciation | Rs m | 3,104 | 136,844 | 2.3% | |
Interest | Rs m | 1,074 | 33,253 | 3.2% | |
Profit before tax | Rs m | 13,048 | 293,523 | 4.4% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,682 | -0.0% | |
Tax | Rs m | 2,980 | -3,584 | -83.1% | |
Profit after tax | Rs m | 10,068 | 105,758 | 9.5% | |
Gross profit margin | % | 13.0 | 27.4 | 47.4% | |
Effective tax rate | % | 22.8 | -1.2 | -1,870.4% | |
Net profit margin | % | 8.7 | 6.2 | 138.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 86,064 | 1,143,425 | 7.5% | |
Current liabilities | Rs m | 37,071 | 997,163 | 3.7% | |
Net working cap to sales | % | 42.2 | 8.6 | 488.9% | |
Current ratio | x | 2.3 | 1.1 | 202.5% | |
Inventory Days | Days | 33 | 91 | 35.9% | |
Debtors Days | Days | 67 | 96 | 70.0% | |
Net fixed assets | Rs m | 37,245 | 552,961 | 6.7% | |
Share capital | Rs m | 239 | 4,167 | 5.7% | |
Net worth | Rs m | 90,447 | 1,880,567 | 4.8% | |
Long term debt | Rs m | 0 | 865,653 | 0.0% | |
Total assets | Rs m | 124,541 | 3,868,976 | 3.2% | |
Interest coverage | x | 13.2 | 9.8 | 133.8% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.4 | 212.8% | |
Return on assets | % | 8.9 | 3.6 | 249.0% | |
Return on equity | % | 11.1 | 5.6 | 197.9% | |
Return on capital | % | 15.6 | 4.9 | 316.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,825 | 269,772 | 6.2% | |
From Investments | Rs m | 1,128 | -95,591 | -1.2% | |
From Financial Activity | Rs m | -17,608 | -323,609 | 5.4% | |
Net Cashflow | Rs m | 416 | -149,429 | -0.3% |
Compare ALKEM LABORATORIES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ALKEM LABORATORIES With: FABINO LIFE BDH INDUS. VINEET LABORATORIES DECIPHER LABS IND. SWIFT
Asian markets traded lower, while the US stock indices ended higher overnight with the S&P 500 hitting a record closing high ahead of key economic data.